NCT04848116View on ClinicalTrials.gov

Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 24, 2021

Primary Completion Date

April 30, 2026

Study Completion Date

September 30, 2026

Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
DRUG

Nivolumab

Nivolumab is an investigational drug in this study.

DRUG

HuMax-IL8

HuMax-IL8 is an investigational drug in this study.

Trial Locations (1)

21287

RECRUITING

Johns Hopkins University, Baltimore

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT04848116 - Neoadjuvant Targeting of Myeloid Cell Populations in Combination With Nivolumab in Head & Neck Ca | Biotech Hunter | Biotech Hunter